Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?
At first glance, you might conclude that the FDA had simply done what it always does with PTC’s unending battle to gain a green light in the US for ataluren: slapped them down.
This time, though, the biotech $PTCT says that regulators are pointing them down a potential accelerated pathway that could lead to an approval. And that would mark a step forward for a company that has recorded nothing but failure for this drug in the clinic over the years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
